# Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

> **NCT06662539** · PHASE2 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 493 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Petrelintide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06662539
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-09
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-03-07
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662539, "Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT06662539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*